MiNK reports early Phase 2 data for agenT-797 in acute lung injury, Q2 2026 results
Initial patients in Ukraine trial showed Day 28 survival and improved oxygenation as MiNK also launched a paid named-patient access program in Brazil.
SEC filing
Latest
1 story